Ardelyx Inc. (ARDX)
NASDAQ: ARDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARDX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $751.60M
- Forward P/E
- 18.92
- EPS (TTM)
- -$0.23
- Dividend yield
- None
- 52-week range
- 2.80 – 8.40
- Day range
- 2.95 – 3.08
- Volume / Avg
- 6.20M / 4.46M
- Beta
- —
- Shares outstanding
- 251.37M
52-week range
ARDX stock today
Shares of Ardelyx (ARDX) finished lower on Nov 20 at $2.99, a drop of 2.29% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 64.4% below their 52-week high of $8.40, set on Jan 23, 2026 and 6.8% above the 52-week low of $2.80, near the bottom of the past year's range. ARDX is down 48.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.8%.
Ardelyx has posted a net loss over the last twelve months (EPS of -$0.23), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Ardelyx
Company profileArdelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael G. Raab
- Headquarters
- Waltham, MA
- Employees
- 489
- IPO year
- 2014
- Website
- ardelyx.com
Financial highlights
Full financialsIn fiscal 2025, Ardelyx generated $407.3 million in revenue, up 22.1% from fiscal 2024, its 7th consecutive year of revenue growth. Ardelyx reported a net loss of $61.6 million, compared with a loss of $39.1 million a year earlier. Gross margin was 90.3% (up from 84.8%) and operating margin -10.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $407.32M | $333.62M | $124.46M | $52.16M | $10.10M |
| Growth | +22.09% | +168.06% | +138.61% | +416.57% | +33.36% |
| Net income | $-61.60M | $-39.14M | $-66.07M | $-67.21M | $-158.16M |
| EPS (diluted) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 |
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$12.50+318.06%
- Strong buy 1
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.00 vs $-0.03
- Surprise
- +100.00%
ARDX news
All ARDX news- Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDXPR Newswire
- ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawPR Newswire
- ARDX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026Business Insider
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDXPR Newswire
- SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDXPR Newswire
- ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026PR Newswire
- Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDXPR Newswire
- ARDX Deadline: ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud LawsuitPR Newswire
Ardelyx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVAInventiva S.A. American Depository Shares | 3.14 | -8.99% | $750.78M | vs ARDX |
| RIGLRigel Pharmaceuticals Inc. | 40.09 | -2.67% | $754.89M | vs ARDX |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs ARDX |
| ORICOric Pharmaceuticals Inc. | 7.36 | -4.42% | $764.94M | vs ARDX |
| COLLCollegium Pharmaceutical Inc. | 24.72 | -1.94% | $768.18M | vs ARDX |
| IRWDIronwood Pharmaceuticals Inc. Class A | 4.70 | -0.21% | $778.09M | vs ARDX |
| SNDXSyndax Pharmaceuticals Inc. | 8.72 | -4.49% | $785.05M | vs ARDX |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs ARDX |
Indexes, lists and sector
Ardelyx stock FAQ
What is Ardelyx's stock price today?
ARDX last traded at $2.99 as of Nov 20, 4:00 PM EST, down 2.29% on the day. Prices are delayed at least 15 minutes.
Who is Ardelyx's CEO?
Mr. Michael G. Raab is the chief executive officer of Ardelyx Inc., which has about 489 employees.
What is the ARDX 52-week high?
The 52-week high for ARDX is $8.40 and the 52-week low is $2.80. The stock is currently 64.4% below its high.